Pyrotinib

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: HER2-positive advanced or metastatic breast cancer with capecitabine after anthracycline... (CN)

This approval is outside the US-scoped market view; the covered program shown here is investigational in the US. Regulatory approval supersedes design-level evidence grading for the approved use.

track record: Partial signal

Also in development:HER2-Positive Breast Cancer · Phase 3 · investigational in the US

Also approved (1)
CN
  • HER2-positive advanced or metastatic breast cancer with capecitabine after anthracycline or taxane (conditional approval); full second-line approval July 2020
Product first approved 20181stoncology.com

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (19)
HER2-Positive Breast Cancer
NCT07892274 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-11-01 – 2031-12-31 · Metastatic Breast Cancer (MBC), HER2-Positive Breast Cancer, Hormone Receptor-Positive Breast Cancer
What this study did
NCT05910398 · RenJi Hospital
2023-06-01 – 2030-08 · Breast Cancer Invasive
What this study did
NCT07615751 · Fudan University
2025-02-12 – 2029-12-30 · Breast Cancer
What this study did
NCT04254263 · RenJi Hospital
2019-12-16 – 2028-08 · Locally Advanced Breast Cancer
What this study did
NCT05346861 · Fudan University
2021-09-15 – 2024-10-31 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT03588091 · Jiangsu HengRui Medicine Co., Ltd.
2018-07-24 – 2024-01-31 · HER2-positive Breast Cancer
What this study did
Non-Small Cell Lung Cancer
Other / comorbidity
NCT05841381 · Fudan University
2023-05-06 – 2033-05-06 · Breast Cancer
What this study did
NCT06278870 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2023-09-06 – 2031-06-30 · HER2-positive Metastatic Breast Cancer, First-line Treatment
What this study did
NCT06144944 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-17 – 2031-01-31 · Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
What this study did
NCT04646759 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2020-10-14 – 2030-12-14 · Breast Cancer
What this study did
NCT07797218 · Shanghai Jiao Tong University School of Medicine
2026-07-01 – 2030-06-30 · Breast Cancer Early Stage Breast Cancer (Stage 1-3)
What this study did
NCT07528716 · Fudan University
2026-05-06 – 2028-06 · Breast Cancer
What this study did
NCT04973319 · Shengjing Hospital
2021-08-01 – 2027-08-01 · Breast Cancer
What this study did
NCT03980054 · Jiangsu HengRui Medicine Co., Ltd.
2019-07-12 – 2027-06 · Breast Cancer
What this study did
NCT03863223 · Jiangsu HengRui Medicine Co., Ltd.
2019-04-22 – 2024-07-30 · Metastatic Breast Cancer
What this study did
NCT05429684 · First Affiliated Hospital Xi'an Jiaotong University
2021-01-01 – 2024-02-28 · HER2+ Breast Cancer
What this study did
NCT02973737 · Jiangsu HengRui Medicine Co., Ltd.
2016-07-20 – 2023-06 · HER2 Positive Metastatic Breast Cancer
What this study did
Phase 2/3 (4)
HER2-Positive Breast Cancer
NCT06958627 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-04-30 – 2027-04-30 · HER2 Positive Breast Cancer, Pyrotinib Treatment
What this study did
Other / comorbidity
NCT07653451 · Peking University Cancer Hospital & Institute
2026-07-01 – 2028-12-31 · Esophageal Squamous Cell Carcinoma
What this study did
NCT04290793 · Hebei Medical University Fourth Hospital
2020-03-01 – 2026-12-10 · Breast Cancer
What this study did
Phase 2 (118)
HER2-Positive Breast Cancer
NCT06973525 · Hebei Medical University Fourth Hospital
2025-09-01 – 2032-05-31 · HER2-positive Breast Cancer
What this study did
NCT07766772 · Fujian Cancer Hospital
2026-09-30 – 2031-12-31 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT07179939 · Fudan University
2025-09-10 – 2031-12-30 · HER2-positive Breast Cancer
What this study did
NCT07019337 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-06-30 – 2030-12-31 · HER2-positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04158856 · xuexin he
2020-06-01 – 2030-05-31 · HER2-positive Breast Cancer
What this study did
NCT05635487 · Shengjing Hospital
2023-03-16 – 2030-02-28 · HER2-positive Breast Cancer
What this study did
NCT06832904 · First Affiliated Hospital of Zhejiang University
2024-12-03 – 2030-01 · HER2-positive Breast Cancer, Neoadjuvant Therapy, Pyrotinib
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT07635342 · Hebei Medical University Fourth Hospital
2024-04-30 – 2029-12-31 · HER2-positive Breast Cancer
What this study did
NCT05582499 · Fudan University
2022-11-01 – 2029-09 · Breast Neoplasm, Breast Cancer, Breast Tumors, Triple-Negative Breast Cancer (TNBC), HER2-positive Breast Cancer, HER2-negative Breast Cancer, Hormone Receptor Positive Tumor, Hormone Receptor Negative Tumor, Early-stage Breast Cancer, Locally Advanced Breast Cancer
What this study did
NCT05834764 · The First Affiliated Hospital with Nanjing Medical University
2023-04-08 – 2028-12-31 · HER2-positive Breast Cancer
What this study did
NCT07132242 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2025-08-30 – 2028-12-31 · Metastatic Breast Cancer With HER2 Positive
What this study did
NCT04398914 · Shanghai Jiao Tong University School of Medicine
2020-05-30 – 2027-12-30 · Breast Cancer Invasive
What this study did
NCT04481932 · Peking University
2020-07 – 2026-12 · HER2-positive Breast Cancer
What this study did
NCT04126525 · RenJi Hospital
2019-06-18 – 2026-11 · Breast Cancer Female
What this study did
NCT04659499 · Peking Union Medical College Hospital
2021-01-01 – 2026-05-15 · Early Breast Cancer
What this study did
NCT05880927 · Taizhou Hospital
2019-01-01 – 2025-12-31 · Breast Cancer
What this study did
NCT06152822 · Tongji Hospital
2023-11-30 – 2025-11-30 · Breast Cancer With Brain Metastases
What this study did
NCT05430347 · The First Affiliated Hospital with Nanjing Medical University
2023-04-15 – 2025-09-30 · Breast Cancer
What this study did
NCT04858516 · Guangdong Provincial People's Hospital
2021-04-30 – 2025-04-30 · Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer
What this study did
NCT05255523 · Fujian Medical University Union Hospital
2022-02-20 – 2024-12-20 · Advanced Breast Cancer
What this study did
NCT04997798 · First Affiliated Hospital of Zhejiang University
2022-09-01 – 2024-12 · Breast Cancer, Estrogen Receptor Positive Tumor, HER2-positive Breast Cancer
What this study did
NCT05429294 · First Affiliated Hospital Xi'an Jiaotong University
2022-06-01 – 2024-10-30 · HER2-positive Breast Cancer
What this study did
NCT05076695 · Fudan University
2021-10-15 – 2024-10-15 · Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03910712 · Peking Union Medical College Hospital
2019-06-01 – 2023-12-01 · Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
What this study did
NCT04605575 · Sun Yat-sen University
2020-05-22 – 2023-12-01 · Breast Cancer, Pyrotinib, Breast Diseases, Vinorelbine, HER2-positive Breast Cancer
What this study did
NCT04088110 · Fuzhou General Hospital
2019-11 – 2023-11 · Breast Cancer Female, HER2-positive Breast Cancer, Hormone Receptor Positive Malignant Neoplasm of Breast, Metastatic Breast Cancer, Breast Diseases, Hormone Receptor Positive Tumor
What this study did
NCT04236310 · Ruijin Hospital
2020-01-15 – 2022-12-31 · Breast Cancer, HER2-positive Breast Cancer, ER-positive Breast Cancer
What this study did
NCT04095390 · Jinming Yu
2019-09-30 – 2022-08-30 · Metastatic Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03919253 · Hebei Medical University Fourth Hospital
2019-04-30 – 2022-04-30 · HER2-positive Breast Cancer
What this study did
NCT04639271 · Shandong Cancer Hospital and Institute
2021-01-01 – 2022-03-01 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT04033172 · Chinese Academy of Medical Sciences
2018-11-01 – 2021-09-01 · Breast Cancer, HER2-positive Breast Cancer
What this study did
NCT03735966 · Henan Cancer Hospital
2018-11-20 – 2020-10-20 · HER2 Positive Breast Cancer
What this study did
NCT04066790 · Shanghai Jiao Tong University School of Medicine
2019-09-09 – 2020-04-30 · Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT06563999 · Sun Yat-sen University
2024-11-01 – 2029-11-01 · Lung Cancer Stage III, Mutation
What this study did
NCT05751018 · Peking Union Medical College Hospital
2021-12-08 – 2026-12-31 · Non-small Cell Lung Cancer
What this study did
NCT06185400 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-02-01 – 2026-12-01 · Non Small Cell Lung Cancer, ERBB2 Mutation-Related Tumors, ERBB2 Gene Duplication, Disitamab Vedotin
What this study did
NCT04144569 · Yongchang Zhang
2019-01-30 – 2024-12-31 · HER2 Insertion Mutation Positive Advanced NSCLC
What this study did
NCT03574402 · Guangdong Association of Clinical Trials
2018-07-09 – 2024-12-30 · Carcinoma, Non-Small-Cell Lung
What this study did
NCT04382300 · Shanghai Chest Hospital
2020-06-30 – 2023-04 · Non-small-cell Lung Cancer
What this study did
NCT04706949 · Fudan University
2020-12-07 – 2022-12-31 · Lung Cancer, Non-small Cell
What this study did
NCT04063462 · Tianjin Medical University Cancer Institute and Hospital
2019-10-01 – 2021-10-01 · Non Small Cell Lung Cancer
What this study did
NCT02834936 · Jiangsu HengRui Medicine Co., Ltd.
2016-10-20 – 2019-06-20 · Non Small Cell Lung
What this study did
NCT02535507 · Tongji University
2015-01 – 2017-12 · Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07393425 · Shanghai Jiao Tong University School of Medicine
2026-02-02 – 2032-09-30 · HER2 + Breast Cancer
What this study did
NCT07340398 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-12-25 – 2031-01-01 · HER2-positive Early Breast Cancer
What this study did
NCT06692491 · Peking University Shenzhen Hospital
2025-01-01 – 2029-12-31 · Rare Tumour
What this study did
NCT07014410 · Zhejiang Cancer Hospital
2023-02-01 – 2029-12-31 · Breast Cancer
What this study did
Phase 1/2 (14)
HER2-Positive Breast Cancer
NCT05575804 · Fudan University
2022-10-01 – 2028-12-31 · Advanced/ Metastatic Her-2 Positive Breast Cancer
What this study did
NCT07708194 · Tianjin Medical University Cancer Institute and Hospital
2025-06-23 – 2027-02 · Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-Positive Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04582968 · Fudan University
2020-01-02 – 2023-08-12 · Breast Cancer, Brain Metastases, HER2-positive Breast Cancer
What this study did
NCT04152057 · West China Hospital
2019-11 – 2021-04 · Breast Cancer, HER2 Positive, Combination Chemotherapy
What this study did
Non-Small Cell Lung Cancer
NCT05745740 · RemeGen Co., Ltd.
2027-12-01 – 2028-12-01 · Non-small Cell Lung Cancer
What this study did
NCT05482568 · Jiangsu HengRui Medicine Co., Ltd.
2022-09-15 – 2026-12 · Advanced Non-small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07189884 · The First Affiliated Hospital of Xiamen University
2025-09-23 – 2028-12-31 · Locally Advanced Breast Cancer (LABC)
What this study did
NCT06718933 · Fudan University
2025-01-08 – 2027-02-28 · Breast Cancer Metastatic, Breast Cancer Brain Metastases
What this study did
NCT06208410 · Risen (Suzhou) Pharma Tech Co., Ltd.
2024-01-11 – 2027-02-26 · Advanced Solid Tumors
What this study did
NCT06015048 · Jiangsu HengRui Medicine Co., Ltd.
2023-08-11 – 2026-12-29 · HER2-expressing Advanced Solid Tumors
What this study did
NCT03772353 · Fudan University
2019-05-12 – 2025-12-10 · Breast Cancer
What this study did
NCT04227041 · Qingdao Zhixin Health Technology Co., Ltd.
2020-01-10 – 2023-01-10 · HER-2 Positive Colorectal Cancer
What this study did
NCT03805399 · Fudan University
2018-10-18 – 2022-12-01 · Triple-negative Breast Cancer
What this study did
NCT02422199 · Jiangsu HengRui Medicine Co., Ltd.
2015-05 – 2018-12 · HER2 Positive Metastatic Breast Cancer
What this study did
Phase 1 (12)
Non-Small Cell Lung Cancer
NCT02500199 · Hengrui Therapeutics, Inc.
2015-06 – 2021-06 · Breast Cancer, Gastric Cancer, Solid Tumors, NSCLC
What this study did
Other / comorbidity
NCT06770296 · The First Affiliated Hospital with Nanjing Medical University
2024-11-01 – 2028-11-01 · Breast Cancer
What this study did
NCT04367090 · Jiangsu HengRui Medicine Co., Ltd.
2020-05-28 – 2023-05-24 · Metastatic Breast Cancer
What this study did
NCT05252546 · Jiangsu HengRui Medicine Co., Ltd.
2022-03-08 – 2022-08-02 · HER2-positive Recurrent / Metastatic Breast Cancer
What this study did
NCT04680091 · Jiangsu HengRui Medicine Co., Ltd.
2020-11-12 – 2021-12-30 · Healthy Subjects, Drug-drug Interaction, Pyrotinib
What this study did
NCT04850651 · Jiangsu HengRui Medicine Co., Ltd.
2021-04-16 – 2021-05-17 · Healthy Subjects
What this study did
NCT04315116 · Jiangsu HengRui Medicine Co., Ltd.
2020-04-13 – 2020-09-01 · Healthy Participants
What this study did
NCT04315493 · Jiangsu HengRui Medicine Co., Ltd.
2020-03 – 2020-04 · Healthy Participants
What this study did
NCT04479891 · Jiangsu HengRui Medicine Co., Ltd.
2019-09-18 – 2019-11-30 · Healthy Subjects
What this study did
NCT02378389 · Jiangsu HengRui Medicine Co., Ltd.
2014-09 – 2017-08 · HER2 Positive Gastric Cancer
What this study did
NCT02361112 · Jiangsu HengRui Medicine Co., Ltd.
2014-08 – 2016-12 · Metastatic Breast Cancer
What this study did
NCT01937689 · Jiangsu HengRui Medicine Co., Ltd.
2013-01 – 2016-12 · Breast Cancer
What this study did
Phase 4 (4)
HER2-Positive Breast Cancer
NCT07600164 · Peking University People's Hospital
2026-07-06 – 2031-12-30 · HER2 + Breast Cancer, Advanced Breast Cancer
What this study did
NCT04929548 · Wuhan University
2022-01-05 – 2027-09-20 · Breast Cancer
What this study did
NCT06217185 · Hebei Medical University Fourth Hospital
2024-01-02 – 2027-06-30 · HER2-positive Breast Cancer, Advanced Breast Cancer
What this study did
Other / comorbidity
NCT06245824 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01-30 – 2026-12-01 · Breast Cancer
What this study did
Early phase / not applicable (10)
HER2-Positive Breast Cancer
NCT06718335 · Nie Jianyun
2024-12-30 – 2029-12-30 · HER2-positive Breast Cancer
What this study did
NCT06015113 · Xi'an International Medical Center Hospital
2023-09 – 2027-04 · Breast Cancer
What this study did
NCT06035679 · Youzhi Zhu
2023-08-17 – 2026-11-30 · Breast Cancer Female
What this study did
NCT03756064 · Zhejiang Cancer Hospital
2019-08-01 – 2021-07-31 · Breast Cancer, Neoplasm, Breast, Breast Diseases
What this study did
NCT03847818 · Shandong University
2019-03-01 – 2021-02-28 · HER2-positive Breast Cancer
What this study did
NCT03947242 · Henan Cancer Hospital
2019-06-01 – 2020-12-30 · HER2 Positive Breast Cancer
What this study did
Other / comorbidity
NCT06495541 · Tianjin Medical University Cancer Institute and Hospital
2026-04-01 – 2028-07-30 · Breast Cancer, RWS, Pyrotinib
What this study did
NCT05560308 · Tianjin Medical University Cancer Institute and Hospital
2022-09-30 – 2025-08-23 · HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy
What this study did
NCT03843749 · Shanghai Changzheng Hospital
2019-07-01 – 2022-07-01 · Colorectal Cancer
What this study did
Used as active comparator (2)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (2)
Other / comorbidity
NCT05424835 · Jiangsu HengRui Medicine Co., Ltd.
2022-08-04 – 2027-12-31 · HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
What this study did
NCT04736589 · Peking Union Medical College
2021-02-02 – 2027-02-02 · Breast Cancer
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, 2 of them ahead of this one.

This drug's own stage for HER2-Positive Breast Cancer: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Pyrotinib: this drugPhase 3Small moleculeEGFR/HER1, HER2, HER4not yet gradedNo reviewed efficacy summary in this indication
Margetuximab (Margenza)ApprovedMonoclonal antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
NeratinibApprovedSmall moleculeEGFR/HER2Reliable signal
NCT00878709: Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2 (From randomization until time of event up to 2 years): Neratinib 4.7 percentage of participants with events vs Placebo 7.5 percentage of participants with events
Palbociclib (Ibrance)ApprovedSmall moleculeCDK4 and CDK6not yet gradedNo reviewed efficacy summary in this indication
PertuzumabApprovedMonoclonal antibodyHER2/neu Receptor AntagonistReliable signal
NCT01358877: IDFS events, pertuzumab + trastuzumab + chemotherapy vs placebo + trastuzumab + chemotherapy: 7.1% vs 8.7%, hazard ratio 0.81 (95% CI 0.66 to 1.00), p=0.0446 (log-rank); 3-year IDFS event-free rate 94.06% vs 93.24% (CT.gov posted results, data cut-off 19 December 2016).
NCT00567190: IRF-assessed progression-free survival, pertuzumab + trastuzumab + docetaxel vs placebo + trastuzumab + docetaxel: median 18.5 vs 12.4 months, hazard ratio 0.62 (95% CI 0.51 to 0.75), p<0.0001 (stratified log-rank; CT.gov posted results).
Trastuzumab DeruxtecanApprovedAntibody–drug conjugateHER2Partial signal
NCT03523585: Progression-Free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-positive, Unresectable and/or Metastatic Breast Cancer Participants Previously Treated With Trastuzumab Emtansine (Baseline up to 46 months postdose): Trastuzumab Deruxtecan (T-DXd) 17.8 months (95% CI 14.3 to 20.8)
Trastuzumab EmtansineApprovedAntibody–drug conjugateHER2 (ERBB2)Partial signalFeatured results are non-efficacy only in this race
TucatinibApprovedSmall moleculeHER2Reliable signal
NCT05132582: HER2CLIMB-05 (NCT05132582), primary endpoint PFS: median 24.9 months with tucatinib vs 16.3 months with placebo; HR 0.641 (95% CI 0.514-0.799); P<.0001.
NCT03975647: Progression-Free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 Based on Investigator Assessment (From the date of randomization to the date of PD or death from any cause or censoring date, whichever occurred first (maximum up to 43 months)): Tucatinib+ Ado-trastuzumab Emtansine 9.5 Months (95% CI 7.4 to 10.9) vs Placebo+ Ado-trastuzumab Emtansine 7.4 Months (95% CI 5.6 to 8.1)
Anbenitamab RepodatecanPhase 3Antibody–drug conjugateHER2 (biparatopic — extracellular domains II and IV)not yet gradedNo reviewed efficacy summary in this indication
Docetaxel (HB1801)Phase 3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab PamirtecanPhase 3Antibody–drug conjugateHER2Partial signal
NCT06265428: NCT06265428, primary endpoint progression-free survival: BNT323/DB-1303 (trastuzumab pamirtecan) vs T-DM1 met the primary PFS endpoint at a pre-specified interim analysis.
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 3Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
BizrolertinibPhase 2/3Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
Disitamab VedotinPhase 2/3Antibody–drug conjugateHER2Partial signal
NCT03500380: Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91).
EvorpaceptPhase 2Protein / enzyme therapeuticCD47not yet gradedNo reviewed efficacy summary in this indication
BBO-10203
Phase 1(overall)
Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(46 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Pyrotinib to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (7)
November 2026 (2)
Phase 1/2HER2-expressing Advanced Solid TumorsRecruiting
Est. primary completion 2026-11 · NCT06015048 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerRecruiting
Est. primary completion 2026-11-30 · NCT06035679 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12 · NCT05482568 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04486911 · CT.gov ↗
What to watch
Phase 2/3Breast CancerActive not recruiting
Est. primary completion 2026-12-01 · NCT04290793 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2026-12-31 · NCT05751018 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT07635342 · CT.gov ↗
What to watch
2027 (16)
February 2027 (2)
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-02 · NCT07708194 · CT.gov ↗
What to watch
Phase 1/2Advanced Solid TumorsRecruiting
Est. primary completion 2027-02-26 · NCT06208410 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-05-31 · NCT06973525 · CT.gov ↗
What to watch
June 2027 (2)
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-06 · NCT03980054 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT06975475 · CT.gov ↗
What to watch
August 2027 (2)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2027-08-01 · NCT04973319 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsRecruiting
Est. primary completion 2027-08-15 · NCT04983121 · CT.gov ↗
What to watch
September 2027 (1)
Phase 2HER2 + Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-11-01 · NCT06563999 · CT.gov ↗
What to watch
December 2027 (7)
Phase 3Breast CancerRecruiting
Est. primary completion 2027-12 · NCT07528716 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-01 · NCT05745740 · CT.gov ↗
What to watch
Early phase / not applicableHER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2027-12-30 · NCT06718335 · CT.gov ↗
What to watch
Phase 2Rare TumourNot yet recruiting
Est. primary completion 2027-12-31 · NCT06692491 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT07014410 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2027-12-31 · NCT05582499 · CT.gov ↗
What to watch
Phase 2/3Esophageal Squamous Cell CarcinomaNot yet recruiting
Est. primary completion 2027-12-31 · NCT07653451 · CT.gov ↗
What to watch
2028 (15)
January 2028 (2)
Phase 2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-01 · NCT06832904 · CT.gov ↗
What to watch
Phase 2Breast NeoplasmsActive not recruiting
Est. primary completion 2028-01-01 · NCT05328440 · CT.gov ↗
What to watch
May 2028 (1)
Phase 3Breast CancerNot yet recruiting
Est. primary completion 2028-05-06 · NCT05841381 · CT.gov ↗
What to watch
June 2028 (1)
Phase 3Breast Cancer Early Stage Breast Cancer (Stage 1-3)Recruiting
Est. primary completion 2028-06-30 · NCT07797218 · CT.gov ↗
What to watch
July 2028 (2)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-07-31 · NCT07019337 · CT.gov ↗
What to watch
August 2028 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2028-08-30 · NCT07132242 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Advanced Breast CancerRecruiting
Est. primary completion 2028-09 · NCT07180082 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07836257 · CT.gov ↗
What to watch
November 2028 (1)
Phase 2Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast CancerRecruiting
Est. primary completion 2028-11-01 · NCT07610720 · CT.gov ↗
What to watch
December 2028 (5)
Phase 3Breast CancerRecruiting
Est. primary completion 2028-12-14 · NCT04646759 · CT.gov ↗
What to watch
Phase 2Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT05769010 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12-30 · NCT07615751 · CT.gov ↗
What to watch
Phase 1/2HER2-Positive Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT05575804 · CT.gov ↗
What to watch
Phase 2HER2-positive Early Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT07340398 · CT.gov ↗
What to watch
2029 (1)
January 2029 (1)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2029-01-31 · NCT07417241 · CT.gov ↗
What to watch
2030 (4)
April 2030 (1)
Phase 3HER2-Positive Breast CancerRecruiting
Est. primary completion 2030-04 · NCT05910398 · CT.gov ↗
What to watch
December 2030 (3)
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-30 · NCT07179939 · CT.gov ↗
What to watch
Phase 2Advanced Digestive System TumorNot yet recruiting
Est. primary completion 2030-12-31 · NCT07053150 · CT.gov ↗
What to watch
Phase 3HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2030-12-31 · NCT07892274 · CT.gov ↗
What to watch
2031 (3)
June 2031 (1)
Phase 3HER2-positive Metastatic Breast Cancer, First-line TreatmentRecruiting
Est. primary completion 2031-06-30 · NCT06278870 · CT.gov ↗
What to watch
December 2031 (2)
Phase 4HER2-Positive Breast CancerRecruiting
Est. primary completion 2031-12-30 · NCT07600164 · CT.gov ↗
What to watch
Phase 2HER2-Positive Breast CancerNot yet recruiting
Est. primary completion 2031-12-31 · NCT07766772 · CT.gov ↗
What to watch

See the full readout calendar ↗